Dexamethasone Doses and Glycemic Response in Diabetic Cholecystectomy

November 11, 2026 updated by: Arwa Mamdouh Mostafa Darwish, Assiut University

Effect of Two Different Doses of Intraoperative Dexamethasone on Glycemic Response in Diabetic Patients Undergoing Laparoscopic Cholecystectomy

This randomized double-blind controlled trial aims to compare the effects of two different doses of intraoperative intravenous dexamethasone (4 mg versus 8 mg) versus placebo on perioperative glycemic response in adult patients with diabetes mellitus undergoing laparoscopic cholecystectomy.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Diabetes mellitus is a common comorbidity in patients undergoing surgery. Perioperative hyperglycemia is associated with increased morbidity. Dexamethasone is frequently administered intraoperatively for its antiemetic and anti-inflammatory effects, but it can cause hyperglycemia.

This randomized double-blind trial will allocate adult patients with established diabetes mellitus scheduled for elective laparoscopic cholecystectomy into three groups: Group I (4 mg dexamethasone), Group II (8 mg dexamethasone), and Group III (placebo). Blood glucose will be measured at predefined time points using a glucometer. The primary outcome is the maximum recorded perioperative blood glucose concentration within 24 hours after dexamethasone administration.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • - Adult patients aged 18 to 60 years.
  • Established diabetes mellitus.
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia.
  • Written informed consent.

Exclusion Criteria:

  • - Patient refusal.
  • Morbid obesity, cardiac diseases, hepatic diseases, or renal diseases.
  • Endocrine disorders affecting glucose metabolism other than diabetes mellitus.
  • Type 1 diabetes mellitus requiring continuous insulin infusion.
  • Poorly controlled diabetes mellitus (HbA1c > 9.0%).
  • ASA physical status III-IV.
  • Recent parenteral or oral steroid therapy.
  • Allergy to dexamethasone.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 4 mg Dexamethasone

Patients will receive 4 mg of intravenous dexamethasone diluted in 0.9% normal saline to 5 mL, administered intravenously over 30 seconds.

Intravenous 4 mg dexamethasone diluted in 0.9% normal saline to 5 mL, administered over 30 seconds.

Other Names:
  • Dexamethasone
Experimental: 8 mg Dexamethasone

Patients will receive 8 mg of intravenous dexamethasone diluted in 0.9% normal saline to 5 mL, administered intravenously over 30 seconds.

Intravenous 8 mg dexamethasone diluted in 0.9% normal saline to 5 mL, administered over 30 seconds.

Other Names:
  • Dexamethasone
Placebo Comparator: Placebo

Patients will receive an equivalent volume of 0.9% normal saline intravenously as placebo.

Equivalent volume of 0.9% normal saline intravenously.

Other Names:
  • Placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Maximum Perioperative Blood Glucose Concentration
Time Frame: At 24 hours

Maximum recorded perioperative blood glucose concentration in mg/dL within 24 hours after dexamethasone administration, measured by finger-prick capillary blood glucose using a glucometer.

At 24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to Peak Blood Glucose Concentration
Time Frame: At 24 hours

Mean time in hours from dexamethasone administration to peak blood glucose concentration.

At 24 hours
Proportion of Patients Developing Hyperglycemia
Time Frame: At 24 hours

Proportion of patients developing blood glucose > 180 mg/dL.

At 24 hours
Proportion of Patients Developing Severe Hyperglycemia
Time Frame: At 24 hours

Proportion of patients developing blood glucose > 200 mg/dL or > 250 mg/dL.

At 24 hours
Requirement for Rescue Insulin
Time Frame: At 24 hours

Proportion of patients requiring rescue insulin during the first 24 postoperative hours.

At 24 hours
Incidence of Hypoglycemia
Time Frame: At 24 hours

Proportion of patients developing blood glucose < 70 mg/dL.

At 24 hours
Postoperative Nausea and Vomiting
Time Frame: At 24 hours

Incidence of postoperative nausea and vomiting.

At 24 hours
Surgical Site Infection
Time Frame: At 30 days

Incidence of surgical site infection.

At 30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Ola M Wahba, prof, Anaesthesia , ICU and pain management Department, Assiut University Hospitals

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 26, 2026

Primary Completion (Estimated)

November 26, 2027

Study Completion (Estimated)

February 25, 2028

Study Registration Dates

First Submitted

November 11, 2026

First Submitted That Met QC Criteria

November 11, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 11, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • Dexa-Diabetic-Chole-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.